Pharmacokinetic effect of AMD070, an oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 5, 2008, Pages 559-565

  Nyunt, Myaing M ^a   Becker, Stephen ^b   MacFarland, Ron T ^c   Chee, Priscilla ^c   Scarborough, Robert ^c   Everts, Stephanie ^a   Calandra, Gary B ^c   Hendrix, Craig W ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Koronis Pharmaceuticals   (United States)

^c GENZYME CORPORATION   (United States)

^d NONE   (United States)

Author keywords

AMD070; CXCR4 inhibitor; CYP2D6; CYP3A4; Drug interaction

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CHEMOKINE RECEPTOR CXCR4; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME SUBSTRATE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; NOSE CONGESTION; OPEN STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINUS TACHYCARDIA; VOLUNTEER; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEXTROMETHORPHAN; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GABA MODULATORS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LEUKOCYTOSIS; MALE; MIDAZOLAM; MIDDLE AGED; RECEPTORS, CXCR4;

EID: 41149169575     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181627566     Document Type: Article

References (31)

1. Schols D, Claes S, Hatse S, et al. Anti-HIVactivity profile of AMD070, an orally bioavailable CXCR4 antagonist [abstract]. Presented at: Conference on Retroviruses Opportunistic Infections; 2003; Boston. Abstract 563.
2. Datema R, Rabin L, Hincenbergs M, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother. 1996;40:750-754.
3. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother. 1994;38:668-674.
4. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1253-1262.
5. Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 2007;51:2351-2358.
6. Cao Y, Flexner C, Dunaway S, et al. Ritonavir increases concentrations of the CXCR4 antagonist AMD070 in healthy volunteers [abstract]. Presented at: Conference on Retroviruses Opportunistic Infections; Los Angeles; 2007. Abstract 570.
7. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
8. Schadel M,Wu D, Otton SV, et al. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15:263-269.
9. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990;265:17209-17214.
10. Wang Z, Gorski JC, Hamman MA, et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317-326.
11. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther. 2004;75:529-538.
12. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511-516.
13. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59:491-502.
14. Kwon Y, Morris ME. Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes. Pharm Res. 1997;14:774-779.
15. Stromberg C, Vanakoski J, Olkkola KT, et al. Exercise alters the pharmacokinetics of midazolam. Clin Pharmacol Ther. 1992;51:527-532.
16. Klotz U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther. 1982;32:107-112.
17. Tolle-Sander S, Rautio J, Wring S, et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res. 2003;20:757-764.
18. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13:129-134.
19. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004;277:3-9.
20. Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther. 2001;70:311-316.
21. Drescher B, Nagel S, Krauter J, et al. AML1/ETO inhibits AML1/CCAAT-enhancer binding protein-alpha mediated activation of the CD11c promoter and represses CD11c expression in HL60 cells. Haematologica. 2003;88:956-958.
22. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-153.
23. Kirby B, Kharasch ED, Thummel KT, et al. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J Clin Pharmacol. 2006;46:1313-1319.
24. Capon DA, Bochner F, Kerry N, et al. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60:295-307.
25. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11:126-135.
26. Marier JF, Deschenes JL, Hage A, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 2005;77:2911-2926.
27. Uhr M, Namendorf C, Grauer MT, et al. P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharmacol. 2004;18:509-515.
28. Di Marco MP, Edwards DJ, Wainer IW, et al. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 2002;71:1149-1160.
29. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45:295-300.
30. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-2730.
31. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1095-1102.